Reply
- PMID: 37490923
- DOI: 10.1097/IAE.0000000000003904
Reply
References
-
- Baumal C, Bliss C, Jones D, Ribeiro R. Correspondence regarding the article: complement inhibition for geographic atrophy: review of salient functional outcomes and perspective. Retina 2023.
-
- Spaide RF, Vavvas DG. Complement inhibition for geographic atrophy: review of salient functional outcomes and perspective. Retina 2023;43:1064–1069.
-
- Kennedy-Shaffer L. When the alpha is the omega: P -values, “substantial evidence,” and the 0.05 standard at FDA. Food Drug Law J 2017;72:595–635.
-
- Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology 2020;127:186–195.
-
- Steinle NC, Pearce I, Monés J, et al. Impact of baseline characteristics on geographic atrophy progression in the FILLY trial evaluating the complement C3 inhibitor pegcetacoplan. Am J Ophthalmol 2021;227:116–124.
Publication types
LinkOut - more resources
Full Text Sources